Brief: Kane Biotech Reports Qtrly Loss Per Share (Post Consolidation) Of $0.009
21/08/2018 22:42
Aug 21 (Reuters) - Kane Biotech Inc KNE.V :
* KANE BIOTECH ANNOUNCES SECOND QUARTER 2018 FINANCIAL
RESULTS
* KANE BIOTECH INC QTRLY LOSS PER SHARE (POST CONSOLIDATION)
OF
$0.009
Source text for Eikon: ID:nGNXbXXck2
Further company coverage: KNE.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update